KR102505375B1 - A cosmetic composition that provides an improved trouble-relieving effect and a method of manufacturing the same - Google Patents
A cosmetic composition that provides an improved trouble-relieving effect and a method of manufacturing the same Download PDFInfo
- Publication number
- KR102505375B1 KR102505375B1 KR1020220151156A KR20220151156A KR102505375B1 KR 102505375 B1 KR102505375 B1 KR 102505375B1 KR 1020220151156 A KR1020220151156 A KR 1020220151156A KR 20220151156 A KR20220151156 A KR 20220151156A KR 102505375 B1 KR102505375 B1 KR 102505375B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- filtrate
- lactobacillus
- fermented
- cosmetic composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000002537 cosmetic Substances 0.000 title claims abstract description 16
- 230000000694 effects Effects 0.000 title description 11
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 31
- 239000000706 filtrate Substances 0.000 claims abstract description 23
- 210000003056 antler Anatomy 0.000 claims abstract description 22
- 241000186660 Lactobacillus Species 0.000 claims abstract description 19
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 19
- 241000566228 Anastatica hierochuntica Species 0.000 claims abstract description 13
- 239000006166 lysate Substances 0.000 claims abstract description 13
- 238000000855 fermentation Methods 0.000 claims abstract description 12
- 230000004151 fermentation Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 241000282994 Cervidae Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000220317 Rosa Species 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- 229940008099 dimethicone Drugs 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 3
- 238000001879 gelation Methods 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 abstract description 8
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 8
- 102000003820 Lipoxygenases Human genes 0.000 description 7
- 108090000128 Lipoxygenases Proteins 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 description 1
- YAZDSTCFFRZJLW-UHFFFAOYSA-N 2-hydroxyicosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCC=CC=CC=CC=C(O)C(O)=O YAZDSTCFFRZJLW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229940031575 hydroxyethyl urea Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- QYZLKGVUSQXAMU-UHFFFAOYSA-N penta-1,4-diene Chemical group C=CCC=C QYZLKGVUSQXAMU-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 description 1
- 229940061570 polyglyceryl-10 stearate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
Description
아래 실시예들은 개선된 트러블 진정 효과를 제공하는 화장료 조성물 및 이의 제조방법 기술에 관한 것이다. The following examples relate to a cosmetic composition that provides an improved trouble soothing effect and a manufacturing method technology thereof.
일반적으로 민감성 피부는 피지 분비량은 적당하나 외부의 자극에 민감해 염증 등을 일으키기 쉬운 피부로 작은 물리적, 화학적인 변화나 자극, 환경적인 외부 요인, 생리적인 내부의 변화에 대해 정상적인 피부보다 매우 민감하게 반응하는 피부를 말한다. 이러한 민감성 피부에 의해 질환으로 습진, 주사형 피부염, 접촉성 피부염 등을 들 수 있으며 그 중에서도 가장 대표적인 질환으로 아토피성 피부염을 들 수 있다.In general, sensitive skin has a moderate amount of sebum secretion, but is sensitive to external stimuli and is prone to inflammation. It is more sensitive than normal skin to small physical and chemical changes or stimuli, environmental external factors, and physiological internal changes. Responsive skin. Diseases caused by such sensitive skin include eczema, rosacea, contact dermatitis, and the like, and among them, atopic dermatitis is the most representative disease.
아토피성 피부염은 알레르기를 가진 사람들에게 나타나는 대표적인 피부 질환의 일종으로 매우 간지러운 만성 염증성 피부염이며 주로 신생아나 유아기에 많이 발생하고 대부분 9세 내지 10세가 되면 자연 치유되나 최근에는 성인이 되어서도 아토피가 지속되는 경우가 늘어나고 있다. 두 돌 이내에 없어지는 경우가 50% 정도이고 25%는 청소년기에 없어지고 나머지 25%는 성인이 되어서도 없어지지 않는다고 한다. 또한 최근에는 환경적인 요인과 스트레스 등으로 인해 성인이 되어 아토피가 처음 발병하는 경우도 급속히 증가하고 있는 추세이다. 국내 의학계에 따르면 우리나라 전체 국민의 약 15% 정도가 아토피성 피부염을 앓고 있다고 한다.Atopic dermatitis is a very itchy chronic inflammatory dermatitis, a typical skin disease that appears in people with allergies. is increasing It is said that about 50% of cases disappear within two years, 25% disappear during adolescence, and the remaining 25% do not disappear even after becoming an adult. Also, in recent years, the number of cases where atopy develops for the first time as an adult due to environmental factors and stress is rapidly increasing. According to the domestic medical community, about 15% of the entire population of Korea suffers from atopic dermatitis.
피부의 수분이 보호되지 않음으로서 피부건조증으로 시작되며 극심한 가려움증을 동반하고 붉게 변하며 피부가 부어 오르면 가렵게 된다. 이에 따라서 자꾸 피부를 긁게 되면 손톱 사이의 세균들에 의해서 염증성 질환으로 발전하게 되어 심한 경우 진물이 나고 딱지가 질 수 있는 병이다.It starts with dry skin as the moisture of the skin is not protected, accompanied by extreme itching, turns red, and becomes itchy when the skin swells. Accordingly, if the skin is repeatedly scratched, it develops into an inflammatory disease by the bacteria between the nails, and in severe cases, it is a disease that can cause exudation and scabs.
염증 반응은 생체나 조직에 물리적 작용이나 화학적 물질, 세균 감염 등의 어떠한 기질적 변화를 가져오는 침습이 가해질 때 그 손상부위를 수복 재생하려는 기전이며, 일단 자극이 가해지면 국소적으로 히스타민, 세로토닌, 브라디키닌, 프로스타글란딘, 하이드록실에이코사테트라에논산(HETE), 류코트리엔과 같은 혈관 활성물질이 유리되어 혈관 괴성이 증대되면서 염증을 유발한다.Inflammatory response is a mechanism to restore and regenerate the damaged area when a living organism or tissue is subjected to invasion that causes any organic change, such as physical action, chemical substance, or bacterial infection. Once stimulation is applied, histamine, serotonin, Vasoactive substances such as bradykinin, prostaglandin, hydroxyleicosatetraenoic acid (HETE), and leukotrienes are released, resulting in increased vascular compaction and inflammation.
대부분의 질환과 마찬가지로 피부 질환 역시 염증 반응을 동반하는데 대표적인 피부 질환인 알레르기 접촉피부염, 건선, 아토피성 피부염 등은 면역세포인 T세포가 매개하는 염증성 질환이다. 따라서 주요 피부 질환에 대한 관리 및 치료에는 반드시 항염증제가 응용되어야 한다. 이러한 염증성 질환을 치료하기 위해 스테로이드성 항염증 제제가 사용되고 있으나 스테로이드성 제제들은 여러 가지 많은 부작용을 나타내고 있어 그 사용을 제한하고 있다. 비스테로이드성 항염 제제도 천연 항균제와 마찬가지로 천연 식물 자원에서 얻어낼 수 있으며 한의학 및 중의학에서 뿐만 아니라 양의학에서도 이미 많은 연구가 진행되고 있다.Like most diseases, skin diseases also accompany inflammatory reactions, and representative skin diseases such as allergic contact dermatitis, psoriasis, and atopic dermatitis are inflammatory diseases mediated by immune cells, T cells. Therefore, anti-inflammatory drugs must be applied to the management and treatment of major skin diseases. Steroidal anti-inflammatory agents are used to treat these inflammatory diseases, but steroidal agents have many side effects, limiting their use. Non-steroidal anti-inflammatory drugs can also be obtained from natural plant resources, like natural antibacterial agents, and many studies have already been conducted not only in oriental medicine and traditional Chinese medicine, but also in western medicine.
본 발명은 상기와 같은 문제점을 해결하기 위한 것으로서, 본 발명자들이 고안한 혼합 발효 추출물이 피부에 대한 진정 효과가 있음을 확인하고, 이에 대한 최적의 제형을 개발하여 본 발명을 완성하였다.The present invention is to solve the above problems, and it was confirmed that the mixed fermented extract designed by the present inventors has a soothing effect on the skin, and the optimal formulation for this was developed to complete the present invention.
실시예들은 피부 트러블을 개선하기 위한 화장료 조성물로서, 혼합 발효 추출물을 제공하고 유효성분에 대한 최적의 제형을 제공하고자 한다.Embodiments are a cosmetic composition for improving skin troubles, to provide a mixed fermented extract and to provide an optimal formulation for active ingredients.
상기 과제를 해결하기 위한 하나의 양태로서, 본 발명은As one aspect for solving the above problems, the present invention
락토바실러스 녹용발효 여과물, 비피더스 발효 용해물, 및 여리고 장미 추출물을 유효성분으로 포함하는, 피부 진정용 화장료 조성물을 제공한다.Provided is a cosmetic composition for skin soothing, comprising a lactobacillus deer antler fermented filtrate, a bifidus fermented lysate, and a rose extract of Jericho as active ingredients.
일 실시예에 따르면, According to one embodiment,
상기 락토바실러스 녹용발효 여과물은 The lactobacillus deer antler fermentation filtrate is
(a) 녹용 1 중량부에 증류수 8 내지 12 중량부를 가한 후 락토바실러스 아시도필루스 (Lactobacillus acidophillus), 락토바실러스 카제이(Lactobacillus casei) 및 락토바실러스 루테리 (Lactobacillus ruteri) 배양액을 첨가하여 배양하는 단계;(a) culturing by adding 8 to 12 parts by weight of distilled water to 1 part by weight of deer antler and then adding culture solutions of Lactobacillus acidophillus, Lactobacillus casei and Lactobacillus ruteri ;
(b) 상기 배양액을 원심분리하고 상등액을 여과지로 여과하는 단계;(b) centrifuging the culture medium and filtering the supernatant through filter paper;
(c) 상기 여과액을 농축하고 건조하여 발효 녹용을 수득하는 단계;(c) concentrating and drying the filtrate to obtain fermented antler;
(d) 상기 발효 녹용 1중량부에 증류수 8 내지 12 중량부를 가한 후 70 내지 90℃의 온도로 추출하는 단계; 및(d) adding 8 to 12 parts by weight of distilled water to 1 part by weight of the fermented deer antler and extracting at a temperature of 70 to 90 ° C; and
(e) 상기 추출된 물질을 여과하고 여과액을 감압농축하는 단계를 포함하여 제조되는 것일 수 있다.(e) it may be prepared by including the step of filtering the extracted material and concentrating the filtrate under reduced pressure.
일 실시예에 따르면, According to one embodiment,
상기 비피더스 발효 용해물은The bifidus fermentation lysate is
(A) 비피도박테리움 비피덤(Bifidobacterium bifidum) 균주를 탈지분유를 90 내지 110g/L 포함하는 배지에 접종하고 2 내지 4일간 배양하는 단계;(A) inoculating a Bifidobacterium bifidum strain into a medium containing 90 to 110 g/L of skim milk powder and culturing for 2 to 4 days;
(B) 상기 배양액을 원심분리하여 상등액을 수득하는 단계;(B) obtaining a supernatant by centrifuging the culture medium;
(C) 상기 상등액 내의 세포를 파쇄하고 여과하여 여과액을 수득하는 단계; 및(C) disrupting the cells in the supernatant and filtering to obtain a filtrate; and
(D) 상기 여과액을 증류수와 1: 0.8 내지 1.2의 중량비로 혼합하는 단계를 포함하여 제조되는 것일 수 있다.(D) mixing the filtrate with distilled water at a weight ratio of 1:0.8 to 1.2.
일 실시예에 따르면, 상기 여리고 장미 추출물은 According to one embodiment, the rose of Jericho extract
(i) 여리고 장미 잎과 줄기 건조물의 분쇄 1 중량부에 8 내지 12 중량부의 에탄올 수용액을 첨가하고 초음파 추출하는 단계;(i) adding 8 to 12 parts by weight of aqueous ethanol solution to 1 part by weight of pulverized dried leaves and stems of Jericho rose, followed by ultrasonic extraction;
(ii) 상기 추출액을 감압여과하는 단계를 포함하여 제조되는 것일 수 있다.(ii) it may be prepared by including the step of filtering the extract under reduced pressure.
일 실시예에 따르면, 상기 화장료 조성물은 수상부, 유상부, 및 겔화용액을 혼합하여 제조된 것이며,According to one embodiment, the cosmetic composition is prepared by mixing the water phase part, the oil phase part, and the gelling solution,
상기 수상부는 상기 락토바실러스 녹용발효 여과물 1.3 내지 1.7 중량%, 상기 비피더스 발효 용해물 0.8 내지 1.2 중량%, 및 상기 여리고 장미 추출물 2.3 내지 2.7 중량%을 포함하고,The aqueous phase part contains 1.3 to 1.7% by weight of the Lactobacillus deer antler fermented filtrate, 0.8 to 1.2% by weight of the bifidus fermented lysate, and 2.3 to 2.7% by weight of the rose extract of Jericho,
상기 유상부는 다이메티콘 0.8 내지 1.2 중량%, 에틸헥실글리세린 1.8 내지 2.2 중량%, 토코페릴아세테이트 3.6 내지 4.4 중량%를 포함하고,The oily phase contains 0.8 to 1.2% by weight of dimethicone, 1.8 to 2.2% by weight of ethylhexylglycerin, and 3.6 to 4.4% by weight of tocopheryl acetate,
상기 겔화용액은 에틸헥실팔미테이트 2.7 내지 3.3 중량% 및 칼슘판토테네이트 1.8 내지 2.2 중량% 포함하는 것일 수 있다. The gelling solution may contain 2.7 to 3.3 wt% of ethylhexyl palmitate and 1.8 to 2.2 wt% of calcium pantothenate.
일실시예에 따른 장치는 하드웨어와 결합되어 상술한 방법들 중 어느 하나의 항의 방법을 실행시키기 위하여 매체에 저장된 컴퓨터 프로그램에 의해 제어될 수 있다.An apparatus according to an embodiment may be combined with hardware and controlled by a computer program stored in a medium to execute any one of the methods described above.
실시예들은 락토바실러스 녹용발효 여과물, 비피더스 발효 용해물, 및 여리고 장미 추출물을 주요 유효성분으로 사용함에 따라 피부 진정을 개선하고 보습 효과를 가진다. 나아가 처방예에 따른 화장료 조성물은 우수한 제제 안정성을 제공한다. In the examples, Lactobacillus antler fermented filtrate, bifidus fermented lysate, and rose Jericho extract were used as main active ingredients to improve skin soothing and have a moisturizing effect. Furthermore, the cosmetic composition according to the prescription provides excellent formulation stability.
이하에서, 첨부된 도면을 참조하여 실시예들을 상세하게 설명한다. 그러나, 실시예들에는 다양한 변경이 가해질 수 있어서 특허출원의 권리 범위가 이러한 실시예들에 의해 제한되거나 한정되는 것은 아니다. 실시예들에 대한 모든 변경, 균등물 내지 대체물이 권리 범위에 포함되는 것으로 이해되어야 한다.Hereinafter, embodiments will be described in detail with reference to the accompanying drawings. However, since various changes can be made to the embodiments, the scope of the patent application is not limited or limited by these embodiments. It should be understood that all changes, equivalents or substitutes to the embodiments are included within the scope of rights.
실시예들에 대한 특정한 구조적 또는 기능적 설명들은 단지 예시를 위한 목적으로 개시된 것으로서, 다양한 형태로 변경되어 실시될 수 있다. 따라서, 실시예들은 특정한 개시형태로 한정되는 것이 아니며, 본 명세서의 범위는 기술적 사상에 포함되는 변경, 균등물, 또는 대체물을 포함한다.Specific structural or functional descriptions of the embodiments are disclosed for illustrative purposes only, and may be modified and implemented in various forms. Therefore, the embodiments are not limited to the specific disclosed form, and the scope of the present specification includes changes, equivalents, or substitutes included in the technical spirit.
제1 또는 제2 등의 용어를 다양한 구성요소들을 설명하는데 사용될 수 있지만, 이런 용어들은 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 해석되어야 한다. 예를 들어, 제1 구성요소는 제2 구성요소로 명명될 수 있고, 유사하게 제2 구성요소는 제1 구성요소로도 명명될 수 있다.Although terms such as first or second may be used to describe various components, such terms should only be construed for the purpose of distinguishing one component from another. For example, a first element may be termed a second element, and similarly, a second element may be termed a first element.
어떤 구성요소가 다른 구성요소에 "연결되어" 있다고 언급된 때에는, 그 다른 구성요소에 직접적으로 연결되어 있거나 또는 접속되어 있을 수도 있지만, 중간에 다른 구성요소가 존재할 수도 있다고 이해되어야 할 것이다.It should be understood that when an element is referred to as being “connected” to another element, it may be directly connected or connected to the other element, but other elements may exist in the middle.
실시예에서 사용한 용어는 단지 설명을 목적으로 사용된 것으로, 한정하려는 의도로 해석되어서는 안된다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 명세서에서, "포함하다" 또는 "가지다" 등의 용어는 명세서 상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.Terms used in the examples are used only for descriptive purposes and should not be construed as limiting. Singular expressions include plural expressions unless the context clearly dictates otherwise. In this specification, terms such as "include" or "have" are intended to designate that there is a feature, number, step, operation, component, part, or combination thereof described in the specification, but one or more other features It should be understood that the presence or addition of numbers, steps, operations, components, parts, or combinations thereof is not precluded.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 실시예가 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the art to which the embodiment belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in the present application, they should not be interpreted in an ideal or excessively formal meaning. don't
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 첨부되는 도면과 함께 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention, and methods of achieving them, will become clear with reference to the detailed description of the following embodiments taken in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in various different forms, only these embodiments make the disclosure of the present invention complete, and common knowledge in the art to which the present invention belongs. It is provided to fully inform the holder of the scope of the invention, and the present invention is only defined by the scope of the claims.
본 발명의 실시예들에서, 별도로 다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 발명의 실시예에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.In the embodiments of the present invention, unless otherwise defined, all terms used herein, including technical or scientific terms, are the same as those commonly understood by one of ordinary skill in the art to which the present invention belongs. It has meaning. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in the embodiments of the present invention, an ideal or excessively formal meaning not be interpreted as
본 발명의 실시예를 설명하기 위한 도면에 개시된 형상, 크기, 비율, 각도, 개수 등은 예시적인 것이므로 본 발명이 도시된 사항에 한정되는 것은 아니다. 또한, 본 발명을 설명함에 있어서, 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우 그 상세한 설명은 생략한다. 본 명세서 상에서 언급된 '포함한다', '갖는다', '이루어진다' 등이 사용되는 경우 '~만'이 사용되지 않는 이상 다른 부분이 추가될 수 있다. 구성 요소를 단수로 표현한 경우에 특별히 명시적인 기재 사항이 없는 한 복수를 포함하는 경우를 포함한다.The shapes, sizes, ratios, angles, numbers, etc. disclosed in the drawings for explaining the embodiments of the present invention are illustrative, so the present invention is not limited to the details shown. In addition, in describing the present invention, if it is determined that a detailed description of related known technologies may unnecessarily obscure the subject matter of the present invention, the detailed description will be omitted. When 'includes', 'has', 'consists of', etc. mentioned in this specification is used, other parts may be added unless 'only' is used. In the case where a component is expressed in the singular, the case including the plural is included unless otherwise explicitly stated.
구성 요소를 해석함에 있어서, 별도의 명시적 기재가 없더라도 오차 범위를 포함하는 것으로 해석한다.In interpreting the components, even if there is no separate explicit description, it is interpreted as including the error range.
도면에서 나타난 각 구성의 크기 및 두께는 설명의 편의를 위해 도시된 것이며, 본 발명이 도시된 구성의 크기 및 두께에 반드시 한정되는 것은 아니다.The size and thickness of each component shown in the drawings are shown for convenience of description, and the present invention is not necessarily limited to the size and thickness of the illustrated components.
본 발명의 여러 실시예들의 각각 특징들이 부분적으로 또는 전체적으로 서로 결합 또는 조합 가능하며, 당업자가 충분히 이해할 수 있듯이 기술적으로 다양한 연동 및 구동이 가능하며, 각 실시예들이 서로에 대하여 독립적으로 실시 가능할 수도 있고 연관 관계로 함께 실시 가능할 수도 있다.Each feature of the various embodiments of the present invention can be partially or entirely combined or combined with each other, and as those skilled in the art can fully understand, various interlocking and driving operations are possible, and each embodiment can be implemented independently of each other. It may be possible to implement together in an association relationship.
이하, 구체적인 실시예와 비교예를 통하여 본 발명의 구성 및 그에 따른 효과를 보다 상세히 설명하고자 한다. 그러나, 본 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것이며, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the configuration of the present invention and its effects will be described in more detail through specific examples and comparative examples. However, these examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples.
제조예 1. 피부진정용 혼합 발효 추출물의 제조Preparation Example 1. Preparation of mixed fermented extract for skin soothing
(1) 락토바실러스 녹용발효 여과물의 제조(1) Preparation of Lactobacillus deer antler fermentation filtrate
녹용 2 ㎏을 0.5 ㎝의 크기로 절단 및 분쇄하였다. 증류수 20 ℓ를 가하여 121℃에서 30분간 멸균한 후, 락토바실러스 아시도필루스 (Lactobacillus acidophillus), 락토바실러스 카제이(Lactobacillus casei) 및 락토바실러스 루테리 (Lactobacillus ruteri) 배양액을 2% 농도로 접종하고 3일 동안 배양하였다. 상기 배양액을 3,000 rpm, 15℃에서 10분 동안 원심분리하여 균주 및 배양 잔사를 제거하였다. 상등액을 여과지(3M paper)로 여과하고, 95℃에서 1시간 동안 가열 살균하여 농축한 후, 분무 건조하여 200 g의 발효 녹용을 수득하였다. 수득한 발효 녹용 200 g을 추출 용기(Ilshin Lab Co., Ltd, FD8512)에 넣고 2ℓ의 물을 첨가하여 80℃에서 60분 추출하였다. 이후 여과지(3M paper)로 여과하여 추출물 액상을 얻었다. 얻어진 추출액 용매를 감압농축기(Sunil EYELA, Rotatory evaporator, N-1N)로 감압 농축하여 9.6 g의 락토바실러스 녹용발효 여과물을 수득하였다.2 kg of antler was cut and ground to a size of 0.5 cm. After adding 20 ℓ of distilled water and sterilizing at 121 ° C. for 30 minutes, Lactobacillus acidophillus, Lactobacillus casei and Lactobacillus ruteri cultures were inoculated at a concentration of 2% and 3 cultured for days. The culture solution was centrifuged at 3,000 rpm and 15° C. for 10 minutes to remove strains and culture residues. The supernatant was filtered with a filter paper (3M paper), concentrated by heating sterilization at 95° C. for 1 hour, and then spray-dried to obtain 200 g of fermented antler. 200 g of the obtained fermented deer antler was placed in an extraction vessel (Ilshin Lab Co., Ltd, FD8512), and 2 L of water was added thereto, followed by extraction at 80° C. for 60 minutes. Thereafter, the extract was filtered with a filter paper (3M paper) to obtain a liquid extract. The obtained extract solvent was concentrated under reduced pressure with a vacuum evaporator (Sunil EYELA, Rotatory evaporator, N-1N) to obtain 9.6 g of Lactobacillus deer antler fermented filtrate.
(2) 비피더스 발효 용해물의 제조(2) Preparation of bifidus fermentation lysate
비피도박테리움 비피덤(Bifidobacterium bifidum) 균주를 탈지분유 배지 (탈지분유 100g/L, 포도당 20g/L, 펩톤 3g/L, 증류수 1g/L)에 접종하고 37℃에서 3일간 배양한 후 원심분리하여 상등액을 얻었다. 이를 호모게나이저로 세포를 파쇄하고 이후 여과지(3M paper)로 여과하여 여과액을 얻었다. 여과액과 증류수를 1:1의 중량비로 혼합하여 비피더스 발효 용해물을 제조하였다.Bifidobacterium bifidum ( Bifidobacterium bifidum ) Inoculate the strain into skim milk medium (skim milk powder 100g / L, glucose 20g / L, peptone 3g / L, distilled water 1g / L), incubate at 37 ° C. for 3 days, and then centrifuge to obtain the supernatant. The cells were disrupted with a homogenizer and then filtered with a filter paper (3M paper) to obtain a filtrate. A bifidus fermentation lysate was prepared by mixing the filtrate and distilled water in a weight ratio of 1:1.
(3) 여리고장미 추출물의 제조(3) Preparation of Jericho rose extract
여리고장미 (Anastatica hierochuntica) 잎과 줄기 건조물 100g을 믹서를 이용하여 분쇄한 후, 40 v/v% 에탄올 수용액 1,000 ml을 첨가하고, 실온에서 초음파 추출기로 4시간 동안 추출하였다. 여과지(Whatman Paper Filter No.3)를 이용하여 1차 감압여과하고 4일 동안 냉장보관하고 침전물이 생성되면 2차 감압여과를 통하여 최종적으로 여리고장미 추출물을 수득하였다.After pulverizing 100 g of dry leaves and stems of Jericho rose ( Anastatica hierochuntica ) using a mixer, 1,000 ml of 40 v / v% ethanol aqueous solution was added, and extracted at room temperature with an ultrasonic extractor for 4 hours. After the first filtration under reduced pressure using a filter paper (Whatman Paper Filter No. 3) and refrigeration for 4 days, when a precipitate was formed, the extract of the rose of Jericho was finally obtained through the second filtration under reduced pressure.
(4) 조성물의 배합(4) Formulation of the composition
상기 락토바실러스 녹용발효 여과물, 비피더스 발효 용해물, 및 여리고 장미 추출물을 아래와 같은 비율로 배합하여 혼합발효 추출물을 제조하였다.A mixed fermented extract was prepared by combining the Lactobacillus deer antler fermented filtrate, the bifidus fermented lysate, and the Jericho rose extract in the following ratio.
실험예 1. 리폭시게나아제 활성 저해 효과Experimental Example 1. Lipoxygenase activity inhibitory effect
리폭시게나제(5-LO, 5-lipoxygenase)는 리놀산, 리놀렌산, 아라키돈산과 같이 분자 내에 1,4-cis,cis-pentadiene(1,4-pentadiene) 구조를 갖는 불포화 지방산에 분자상 산소를 첨가하여 1,3-cis, trans-diene 5-hydroperoxide를 생성하는 산화효소로 아라키돈산으로부터 각종 염증 및 알러지성 질환에 관여하는 로이코트리엔(leucotriene) 생합성의 첫번째 반응에 관여하는 효소이다. 따라서 구조적, 메커니즘적으로 5-LO와 유사한 SLO(soybean lipoxygenase)를 이용하여 리폭시게나제의 저해활성을 측정하여 항염효과를 확인하였다. 즉, 0.1M Tris 완충용액 200㎕에 2㎕의 시료를 첨가하고, 여기에 500 unit의 15-lipoxygenase를 넣어서 25에서 5분간 반응시켰다. 반응 후, 에탄올에 녹인 linolenic acid를 최종농도 110μM이 되도록 첨가하여 섞은 후 234nm에서 5분간 흡광도를 측정하여 시료를 첨가하지 않은 대조군 대비 혼합발효 추출물의 리폭시게나제 저해활성(%)을 계산하였다. Lipoxygenase (5-LO, 5-lipoxygenase) adds molecular oxygen to unsaturated fatty acids having a 1,4- cis,cis -pentadiene (1,4-pentadiene) structure in the molecule, such as linoleic acid, linolenic acid, and arachidonic acid. As an oxidase that generates 1,3- cis, trans -diene 5-hydroperoxide, it is an enzyme involved in the first reaction of leucotriene biosynthesis from arachidonic acid, which is involved in various inflammatory and allergic diseases. Therefore, the anti-inflammatory effect was confirmed by measuring the inhibitory activity of lipoxygenase using SLO (soybean lipoxygenase), which is structurally and mechanically similar to 5-LO. That is, 2 μl of the sample was added to 200 μl of 0.1M Tris buffer, and 500 units of 15-lipoxygenase were added thereto and reacted at 25°C for 5 minutes. After the reaction, linolenic acid dissolved in ethanol was added to a final concentration of 110 μM, mixed, and absorbance was measured at 234 nm for 5 minutes to calculate the lipoxygenase inhibitory activity (%) of the mixed fermented extract compared to the control group to which no sample was added.
이와 같이 같은 용량으로 비교하였을 때 여리고 장미 추출물 단독에 비해 혼합 추출물이 리폭시게나제 저해활성이 우수하였으며, 특히 두 발효 추출물을 모두 혼합한 경우에 시너지 효과가 있음을 확인할 수 있었다. 이러한 활성으로부터 실시예 1의 혼합 발효 추출물은 피부 진정 효과가 우수하여 화장료 조성물 개발이 가능할 것으로 판단되었다.As such, when compared at the same dose, the mixed extract had superior lipoxygenase inhibitory activity compared to the Jericho rose extract alone, and in particular, it was confirmed that a synergistic effect was obtained when both fermented extracts were mixed. From this activity, it was determined that the mixed fermented extract of Example 1 had an excellent skin soothing effect, enabling the development of a cosmetic composition.
실험예 2. DPPH 소거능에 의한 항산화 효과Experimental Example 2. Antioxidant effect by DPPH scavenging ability
활성 산소에 의한 피부 노화 과정은 지질 과산화, DNA 산화, 멜라닌 생성, 결합조직의 절단 및 비정상적인 교차 결합들을 포함한다. 이들 반응들은 거의 대부분 라디칼 반응으로서 자동산화반응 과정이 포함된다. 생체 내에서 자동산화반응을 차단시키는 역할은 항산화제가 담당하고 있다. 전자를 주는 능력으로서 환원력이 클수록 강한 항산화제가 된다.The skin aging process by reactive oxygen species includes lipid peroxidation, DNA oxidation, melanin production, cleavage of connective tissue, and abnormal cross-links. Most of these reactions are radical reactions, which include autoxidation reactions. Antioxidants play a role in blocking autoxidation reactions in vivo. As the ability to donate electrons, the greater the reducing power, the stronger the antioxidant.
항산화제의 환원력을 측정하는 시약으로 1,1-diphenyl-2 picrylhydrazyl radical(DPPH)가 있다. DPPH는 화합물 내 질소 중심의 안정화된 구조의 라디칼로 존재한다. 517nm에서 최대 흡수를 나타내며 환원되면 517nm에서 흡수가 없어진다. 시료 100μL와 60μM의 DPPH 용액 100μL를 96 well plate에 분주하여 실온에서 30분간 반응시킨 후 흡광도를 측정하여 시료를 첨가하지 않은 대조군 대비 흡광도가 감소된 %를 측정하였다.As a reagent for measuring the reducing power of antioxidants, there is 1,1-diphenyl-2 picrylhydrazyl radical (DPPH). DPPH exists as a radical of a stabilized structure of the nitrogen center in the compound. It shows a maximum absorption at 517 nm, and when reduced, the absorption disappears at 517 nm. 100 μL of the sample and 100 μL of a 60 μM DPPH solution were dispensed into a 96 well plate, reacted at room temperature for 30 minutes, and then the absorbance was measured to measure the percent decrease in absorbance compared to the control group to which no sample was added.
실험예 1과 마찬가지로, 같은 전체 용량을 첨가하였을 때, 여리고 장미 추출물 단독에 비해 혼합 추출물이 DPPH 저해활성이 우수하였으며, 특히 두 발효 추출물을 모두 혼합한 경우에 시너지 효과가 있음을 확인할 수 있었다. 이러한 활성으로부터 실시예 1의 혼합 발효 추출물은 피부 진정 효과가 우수하여 화장료 조성물 개발이 가능할 것으로 판단되었다.As in Experimental Example 1, when the same total amount was added, the DPPH inhibitory activity of the mixed extract was superior to that of the Jericho rose extract alone, and in particular, it was confirmed that there was a synergistic effect when both fermented extracts were mixed. From this activity, it was determined that the mixed fermented extract of Example 1 had an excellent skin soothing effect, enabling the development of a cosmetic composition.
제조예 2. 실시예 1 기반 화장료 조성물 제조 처방에의 제조Preparation Example 2. Preparation of a cosmetic composition based on Example 1 as a prescription
아래 표 4에서 수상부를 75 ℃가 되도록 가열하고, 유상부를 75 ℃가 되도록 가열하였다. 가열된 수상부 및 유상부로 혼합한 후 75 ℃에서 호모믹서기로 5분 동안 유화하여 에멀젼을 제조하였다. 제조된 에멀젼에 겔화용액을 첨가한 후 75 ℃를 유지하면서 30분 동안 교반하여 하이드로겔 조성물을 제조하였다.In Table 4 below, the water phase part was heated to 75 ° C, and the oil phase part was heated to 75 ° C. After mixing the heated aqueous phase and the oil phase, an emulsion was prepared by emulsifying at 75 ° C. for 5 minutes with a homomixer. A hydrogel composition was prepared by adding a gelation solution to the prepared emulsion and stirring for 30 minutes while maintaining 75 ° C.
실험예 3. 제형의 물리적 특성 및 안정성Experimental Example 3. Physical properties and stability of the formulation
비교처방예1는 유화가 잘 되지 않아 점성이 높아 끈적이고 뭉침현상이 강하였던 반면, 비교 처방예 2 와 처방예 1은 끈적임이 적고 뭉침현상이 나타나지 않았다. 제형들을 50℃에서 1개월간 보관한 결과, 비교처방예 1 및 2에서는 유상이 분리되는 현상이 나타난 반면, 실시예 1에서는 유상분리가 나타나지 않아 에틸헥실팔미테이트와 칼슘판토네이트를 사용한 경우 우수한 제형 안정성을 가짐을 알 수 있었다.Comparative Prescription Example 1 did not emulsify well and had high viscosity, making it sticky and agglomeration was strong, whereas Comparative Prescription Example 2 and Prescription Example 1 were less sticky and did not show agglomeration. As a result of storing the formulations at 50 ° C for 1 month, the oil phase was separated in Comparative Prescription Examples 1 and 2, whereas the oil phase was not separated in Example 1, so when ethylhexyl palmitate and calcium pantonate were used, excellent formulation stability was found to have
실험예 4. 피부 수분량 측정Experimental Example 4. Measurement of skin moisture content
평가대상으로 30세의 여성 30명을 선정하여 시험부위인 안면을 세척하고, 온도 20±3 ℃및 상대습도 40±2 %의 항온항습 조건에서 피부를 적응시켰다. 이 후, 처방예 1 및 경쟁사 A사의 제품 화장료 조성물을 적용하였다. 이후, CK electronic(Germany)사의 Tewameter TM300을 사용하여 0분, 30분, 60분, 90분, 120분 후의 경표피 수분 손실량을 측정하였다. 실험은 5회 측정하여 그 평균값을 계산하였으며, 그 결과를 하기 표 5에 나타내었다.Thirty 30-year-old women were selected as evaluation subjects, the test site, the face, was washed, and the skin was acclimatized under constant temperature and humidity conditions of 20 ± 3 ° C and 40 ± 2% relative humidity. After that, the product cosmetic composition of Prescription Example 1 and competitor A was applied. Thereafter, the amount of transepidermal water loss after 0 minutes, 30 minutes, 60 minutes, 90 minutes, and 120 minutes was measured using Tewameter TM300 from CK electronic (Germany). The experiment was measured 5 times and the average value was calculated, and the results are shown in Table 5 below.
이와 같이 처방예를 사용한 경우 다른 경쟁사 제품 대비 보습 효과가 있으며 이에 따라 피부 진정 효과가 나타날 수 있음을 확인할 수 있었다.In the case of using the prescription example as described above, it was confirmed that there was a moisturizing effect compared to other competitor's products, and thus a skin soothing effect could be obtained.
Claims (3)
상기 락토바실러스 녹용발효 여과물은
(a) 녹용 1 중량부에 증류수 8 내지 12 중량부를 가한 후 락토바실러스 아시도필루스 (Lactobacillus acidophillus), 락토바실러스 카제이(Lactobacillus casei) 및 락토바실러스 루테리 (Lactobacillus ruteri) 배양액을 첨가하여 배양하는 단계;
(b) 상기 배양액을 원심분리하고 상등액을 여과지로 여과하는 단계;
(c) 상기 여과액을 농축하고 건조하여 발효 녹용을 수득하는 단계;
(d) 상기 발효 녹용 1중량부에 증류수 8 내지 12 중량부를 가한 후 70 내지 90℃의 온도로 추출하는 단계; 및
(e) 상기 추출된 물질을 여과하고 여과액을 감압농축하는 단계를 포함하여 제조되는 것이고;
상기 비피더스 발효 용해물은
(A) 비피도박테리움 비피덤(Bifidobacterium bifidum) 균주를 탈지분유를 90 내지 110g/L 포함하는 배지에 접종하고 2 내지 4일간 배양하는 단계;
(B) 상기 배양액을 원심분리하여 상등액을 수득하는 단계;
(C) 상기 상등액 내의 세포를 파쇄하고 여과하여 여과액을 수득하는 단계; 및
(D) 상기 여과액을 증류수와 1: 0.8 내지 1.2의 중량비로 혼합하는 단계를 포함하여 제조되는 것이고;
상기 여리고 장미 추출물은
(i) 여리고 장미 잎과 줄기 건조물의 분쇄 1 중량부에 8 내지 12 중량부의 에탄올 수용액을 첨가하고 초음파 추출하는 단계;
(ii) 상기 추출액을 감압여과하는 단계를 포함하여 제조되는 것이며;
상기 화장료 조성물은 수상부, 유상부, 및 겔화용액을 혼합하여 제조된 것이며,
상기 수상부는 상기 락토바실러스 녹용발효 여과물 1.3 내지 1.7 중량%, 상기 비피더스 발효 용해물 0.8 내지 1.2 중량%, 및 상기 여리고 장미 추출물 2.3 내지 2.7 중량%을 포함하고,
상기 유상부는 다이메티콘 0.8 내지 1.2 중량%, 에틸헥실글리세린 1.8 내지 2.2 중량%, 토코페릴아세테이트 3.6 내지 4.4 중량%를 포함하고,
상기 겔화용액은 에틸헥실팔미테이트 2.7 내지 3.3 중량% 및 칼슘판토테네이트 1.8 내지 2.2 중량% 포함하는 것인, 피부 진정용 화장료 조성물.
A cosmetic composition for skin soothing, comprising Lactobacillus antler fermented filtrate, bifidus fermented lysate, and Jericho rose extract as active ingredients,
The lactobacillus deer antler fermentation filtrate is
(a) culturing by adding 8 to 12 parts by weight of distilled water to 1 part by weight of deer antler and then adding culture solutions of Lactobacillus acidophillus, Lactobacillus casei and Lactobacillus ruteri ;
(b) centrifuging the culture medium and filtering the supernatant through filter paper;
(c) concentrating and drying the filtrate to obtain fermented antler;
(d) adding 8 to 12 parts by weight of distilled water to 1 part by weight of the fermented deer antler and extracting at a temperature of 70 to 90 ° C; and
(e) filtering the extracted material and concentrating the filtrate under reduced pressure;
The bifidus fermentation lysate is
(A) inoculating a Bifidobacterium bifidum strain into a medium containing 90 to 110 g/L of skim milk powder and culturing for 2 to 4 days;
(B) obtaining a supernatant by centrifuging the culture medium;
(C) disrupting the cells in the supernatant and filtering to obtain a filtrate; and
(D) mixing the filtrate with distilled water at a weight ratio of 1:0.8 to 1.2;
The Jericho rose extract
(i) adding 8 to 12 parts by weight of aqueous ethanol solution to 1 part by weight of pulverized dried leaves and stems of Jericho rose, followed by ultrasonic extraction;
(ii) it is prepared by including the step of filtering the extract under reduced pressure;
The cosmetic composition is prepared by mixing an aqueous phase part, an oil phase part, and a gelling solution,
The aqueous phase part contains 1.3 to 1.7% by weight of the Lactobacillus deer antler fermented filtrate, 0.8 to 1.2% by weight of the bifidus fermented lysate, and 2.3 to 2.7% by weight of the rose extract of Jericho,
The oily phase contains 0.8 to 1.2% by weight of dimethicone, 1.8 to 2.2% by weight of ethylhexylglycerin, and 3.6 to 4.4% by weight of tocopheryl acetate,
The gelation solution is a cosmetic composition for skin soothing, containing 2.7 to 3.3% by weight of ethylhexyl palmitate and 1.8 to 2.2% by weight of calcium pantothenate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220151156A KR102505375B1 (en) | 2022-11-14 | 2022-11-14 | A cosmetic composition that provides an improved trouble-relieving effect and a method of manufacturing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220151156A KR102505375B1 (en) | 2022-11-14 | 2022-11-14 | A cosmetic composition that provides an improved trouble-relieving effect and a method of manufacturing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102505375B1 true KR102505375B1 (en) | 2023-03-02 |
Family
ID=85509039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220151156A KR102505375B1 (en) | 2022-11-14 | 2022-11-14 | A cosmetic composition that provides an improved trouble-relieving effect and a method of manufacturing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102505375B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100994987B1 (en) | 2008-03-31 | 2010-11-18 | 주식회사 씨앤피차앤박화장품 | Cosmetic composition with the calming effect for skins |
KR20140004047A (en) * | 2013-12-02 | 2014-01-10 | 주식회사 엘지생활건강 | Anti-wrinkle cosmetic composition |
KR20160068327A (en) | 2014-12-05 | 2016-06-15 | 코웨이 주식회사 | Cosmetic Composition Comprising Anastatica hierochuntica extracts for protecting skin from stress due to harmful environment |
KR20180057329A (en) * | 2016-11-22 | 2018-05-30 | 주식회사 트루자임 | A fermented composition for improving atopic dermatitis contaning natural extract |
KR20220098594A (en) * | 2021-01-04 | 2022-07-12 | 주식회사 바이오케어 | Composition for preventing, improving or treating atopic or allergic dermatitis comprising deer antler fermentation products as an active ingredient |
-
2022
- 2022-11-14 KR KR1020220151156A patent/KR102505375B1/en active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100994987B1 (en) | 2008-03-31 | 2010-11-18 | 주식회사 씨앤피차앤박화장품 | Cosmetic composition with the calming effect for skins |
KR20140004047A (en) * | 2013-12-02 | 2014-01-10 | 주식회사 엘지생활건강 | Anti-wrinkle cosmetic composition |
KR20160068327A (en) | 2014-12-05 | 2016-06-15 | 코웨이 주식회사 | Cosmetic Composition Comprising Anastatica hierochuntica extracts for protecting skin from stress due to harmful environment |
KR20180057329A (en) * | 2016-11-22 | 2018-05-30 | 주식회사 트루자임 | A fermented composition for improving atopic dermatitis contaning natural extract |
KR20220098594A (en) * | 2021-01-04 | 2022-07-12 | 주식회사 바이오케어 | Composition for preventing, improving or treating atopic or allergic dermatitis comprising deer antler fermentation products as an active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101485896B1 (en) | Cosmetic composition for improving anti-oxidation, anti-inflammatory and atopic skin and method of preparing the same | |
KR100863890B1 (en) | Cosmetic composition containing extracts of inonotus obliquus, fomitopsis officinalis, agarikus blazei murill and hericium erinaceum | |
KR101716106B1 (en) | Seaweed mixed fermentation with an anti-inflammatory, anti-allergic and atopic skin improvement, a preparation method thereof and a cosmetic composition of the same | |
JP2024073584A (en) | Method for preparing Dendrobium arborescens extract, method for preparing Dendrobium arborescens extract derivative and application thereof | |
KR20120058202A (en) | Vegetable antibacterial composition and cosmetic composition for improving skin using the same | |
KR20150139298A (en) | Skin external composition containing hongguk extract for skin moisturizing | |
KR20180082056A (en) | A functional cosmetic composition comprising natural complex extract | |
KR102009676B1 (en) | Cosmetic Composition Comprising Bamboo Fermented Extract | |
KR100994987B1 (en) | Cosmetic composition with the calming effect for skins | |
KR101397160B1 (en) | Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance | |
KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
KR102505375B1 (en) | A cosmetic composition that provides an improved trouble-relieving effect and a method of manufacturing the same | |
KR102119524B1 (en) | Cosmetic composition comprising the extract of fermented Sprout leaf/stem ginseng for skin anti-wrinkle effect and producing method thereof | |
KR102491557B1 (en) | Peptide and oside extract of schizandra fruit and improvement in the response of the cutaneous neurosensory system | |
KR102075849B1 (en) | Composition for skin moisturizing and anti-inflammation and enhancing skin barrier comprising Aureobasidium pullulans extract as effective component | |
KR101854444B1 (en) | A cosmetic composition for the prevention and improvement of striae distensae containing a extract of cynara scolymus | |
KR102421800B1 (en) | Composition comprising fermented extract of Halophilic microorganism | |
KR102258283B1 (en) | Inflammation or allergy treatment and improvement composition comprising a natural product fermentation complex extract as an active ingredient and a method of manufacturing the same | |
KR20180082057A (en) | A cosmetic composition containing lactobacillus-fermented extract for improving atopic dermatitis | |
JP2011088854A (en) | Involucrin expression inhibitor | |
CN107303255B (en) | Sorghum fermentation product having anti-inflammatory, anti-allergic and atopic skin improving effects, its preparation method and cosmetic composition | |
KR20160055118A (en) | Cosmetic composition comprising of the mixed herb fermentes and preparation method of the same | |
KR100479665B1 (en) | Cosmetic compositions containing fermented extracts of green tea, dehulled rice and taraxacum herb | |
KR102533040B1 (en) | Composition for antioxidation or anti-inflammation comprising fermented extracts of Phellodendron amurense bark, Saururus chinensis, Platycarya strobilacea fruit and Diospyros kaki leaf as active ingredients, and method for preparing the same | |
KR102558754B1 (en) | Cosmetic composition comprising fermented extraction of carrot leaf |